# AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.

Source: https://onco.cc/trials/nct07208539/  
OnCo record `nct07208539` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Shanghai Zhongshan Hospital, not yet recruiting.

## Summary

AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer. is a phase 2, interventional study registered as NCT07208539 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 77 participants, started 2025-10-10 and due to reach its primary completion in 2026-04-09. Interventions recorded: Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1. Conditions listed: Pancreatic Cancer. Primary outcome: 18-month overall survival (OS) rate. Pancreatic eligibility wording from the registry: "* According to the NCCN Clinical Practice Guidelines for Pancreatic Cancer (2024". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: ZSPAC-14
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07208539
- Phase: 2
- Setting: A Prospective, Double-cohort, Multicenter, Phase II Study of Gemcitabine and Albumin Paclitaxel in Combination With PD-L1 Antibodies Followed by Liposomal Irinotecan Combined With Oxaliplatin, 5-FU/LV and PD-L1 Antibodies as Conversion Therapy for Borderline Resectable/Local Advanced Pancreatic Cancer
- Sponsor: Shanghai Zhongshan Hospital
- Enrolled: 77

## Sources

- ClinicalTrials.gov NCT07208539: https://clinicaltrials.gov/study/NCT07208539

## Connected records

- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07208539.json